Baseline characteristics of the study population (n=115)
Variable | Value |
---|---|
Age, years (mean±SD) | 50.22±14.24 |
Sex, female (%) | 72 (62.6) |
Size, cm (mean±SD) | 1.89±1.46 |
Multifocal tumors, number (%) | 23 (20.0) |
Bilateral tumors, number (%) | 18 (15.7) |
RET mutation, number (%) | |
Positive | 16/76 (21.1) |
Negative | 60/76 (78.9) |
T stage, number (%) | |
1a | 40 (34.8) |
1b | 27 (23.5) |
2 | 19 (16.5) |
3a | 7 (6.1) |
3b | 13 (11.3) |
4a | 9 (7.8) |
N stage, number (%) | |
0 | 47 (40.9) |
1a | 18 (15.6) |
1b | 50 (43.5) |
AJCC 8th stage, number (%) | |
I | 37 (32.2) |
II | 10 (8.7) |
III | 18 (15.6) |
IVA | 50 (43.5) |
Preoperative serum calcitonin, pg/mL | |
Mean | 1,188 |
Median | 336 |
Range | 4-17,200 |
Preoperative serum CEA, ng/mL | |
Mean | 32.3 |
Median | 6.4 |
Range | 0.5-475.7 |
Follow-up duration, years | |
Median (IQR) | 8.3 (4.9-10.8) |
Clinical outcome, number (%) | |
No evidence of structural recurrence confirmed by sonography | 80 (69.6%) |
Local metastasis confined to neck lymph nodes | 15 (13.0%) |
Distant metastasis confirmed by CT or PET scans | 13 (11.3%) |
Death | 7 (6.1%) |
AJCC: American Joint Committee on Cancer, CEA: carcinoembryonic antigen, CT: computerized tomography, IQR: interquartile range, MTC: medullary thyroid carcinoma, PET: positron emission tomography, SD: standard deviation